Amneal’s specialty segment grew 23% in Q1 2026 — not the generics engine the company was built on, but the branded neurology and endocrinology portfolio that now increasingly defines its margin profile. That asymmetry matters. Total net revenue reached $723 million against $695 million a year ago, a modest 4% headline gain that understates what’s actually happening inside the business. Gross margin expanded 750 basis points year-over-year, driven almost entirely by the deliberate contraction of AvKARE’s low-margin distribution channel. Net income jumped 411% to $62 million. These are not the numbers of a generics manufacturer grinding through price erosion.
The strategic pivot is accelerating into the Kashiv transaction. Kashiv Biosciences — a related-party entity controlled by the Patel family — brings biosimilar and complex injectable capabilities that Amneal is folding in precisely when its branded portfolio is generating enough cash to absorb integration costs without diluting the growth narrative. CREXONT, the extended-release carbidopa-levodopa therapy for Parkinson’s, and BREKIYA, its recently launched autoinjector, are doing the heavy lifting in specialty. UNITHROID is a steady contributor in endocrinology. Together they’re reshaping the revenue mix fast enough that the generics label is becoming a liability more than an identity.
Full-year 2026 guidance sits at $3.05–$3.15 billion in net revenue with adjusted EBITDA of $740–$770 million. Operating cash flow guidance of $350–$400 million — or $375–$425 million excluding discrete legal settlement payments — gives the company genuine financial flexibility. That matters because Amneal is carrying meaningful debt and the Kashiv deal adds complexity to the balance sheet. The margin expansion story only sustains itself if specialty revenue continues to compound and biosimilar launches in the Affordable Medicines segment land with enough volume to offset ongoing generic price compression.
The single number worth tracking through the rest of 2026 is specialty’s share of total net revenue. It’s the clearest indicator of whether Amneal’s repositioning as a branded-led company with a generics base holds — or whether the generics drag eventually reasserts itself and compresses the multiple the market is beginning to assign to AMRX.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
